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Abstract
Background—Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) 
improves survival modestly but new strategies are needed. This trial was designed to evaluate an 
antivascular endothelial growth factor strategy with or without standard chemotherapy in 
previously treated NSCLC.
Methods—Patients with stage IIIB/IV NSCLC with performance status 0 to 1 progressive after 
first-line chemotherapy were eligible for randomization to pemetrexed, sunitinib, or the 
combination. Patients were stratified by performance status, stage, and sex. Primary objective was 
18-week progression-free survival (PFS) rate; secondary objectives included response, overall 
survival (OS), and toxicity. Target accrual was 225. The study was terminated early because of 
decreasing accrual rates.
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Results—Between April 2008 and September 2011, 130 patients were registered and 
randomized; of this, 125 patients were treated. Baseline characteristics in the three arms were well 
balanced. Toxicity was higher in the sunitinib-containing arms. The 18-week PFS rate in the 
pemetrexed, sunitinib, and combination arms was 54% (95% confidence interval [CI], 40–71), 
37% (95% CI, 25–54), and 48% (95% CI, 35–66), respectively (p= 0.25). Median PFS in the 
pemetrexed, sunitinib, and combination arms in months was 4.9 (2.1–8.8), 3.3 (2.3–4.2), and 3.7 
(2.5–5.8), respectively (p= 0.18). There was an overall statistically significant difference in OS 
between the three arms: median OS in months was 10.5 (8.3–20.2) for pemetrexed, 8.0 (6.8–13.5) 
for sunitinib, and 6.7 (4.1–10.1) for the combination (p= 0.03).
Conclusion—Pemetrexed had a superior toxicity profile to either sunitinib or the combination of 
pemetrexed and sunitinib. The 18-week PFS rate was not significantly different between the arms. 
OS was significantly better with pemetrexed alone compared with the two sunitinib-containing 
arms, with the doublet performing worst for OS.
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Antiangiogenic therapy as a therapeutic target in non–small-cell lung cancer (NSCLC) was 
demonstrated as beneficial by Eastern Cooperative Oncology Group 4599, which showed 
that the addition of bevacizumab, a monoclonal antibody to vascular endothelial growth 
factor (VEGF), to standard chemotherapy improved overall survival (OS) among advanced 
nonsquamous NSCLC patients treated in the first-line setting.1 Multiple other 
antiangiogenic drugs, including many small-molecule tyrosine kinase inhibitors of VEGF 
receptor (VEGFR), have been developed and are in clinical testing across a broad range of 
tumor types.2-4
We hypothesized that the addition of antiangiogenic therapy to standard chemotherapy in 
the second-line setting could lead to improved outcomes. We therefore designed this 
randomized phase 2 trial to treat patients on one of three arms: Arm I, pemetrexed alone; 
Arm II, sunitinib alone; or Arm III, the combination of pemetrexed and sunitinib, with a 
primary end point of improvement in 18-week progression-free survival (PFS).
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases, including 
VEGFR, platelet-derived growth factor receptor (PDGFR), FGFR1, cKIT, FLT3, and RET 
kinases.5 Sunitinib as monotherapy in patients with advanced NSCLC has been tested in 
multiple studies.6-8 Among previously treated NSCLC patients, at 50 mg/day on a 4-week 
on and 2-week off schedule, overall response rate (RR) was 11.1% with median PFS of 12 
weeks and median OS of 23.4 weeks.8 Subsequent studies in NSCLC showed that 
continuous daily dosing at 37.5 mg/day resulted in similar median PFS of 11.9 weeks and 
median OS of 37.1 weeks.7 On the basis of these phase 2 data, sunitinib was a rational 
choice to test in the second-line setting, either as monotherapy or combined with second-line 
chemotherapy. Combination of sunitinib, at either 37.5 mg/day continuous dosing or 50 
mg/day on a 2-week on and 1-week off schedule, with pemetrexed at 500 mg/m2 on day 1 of 
every 21 days, has been found to be well tolerated in the phase 1 setting.9
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Patients aged 18 years or older with histologically or cytologically proven advanced NSCLC 
(stage IIIB or IV) with evidence of progression after first-line therapy were eligible. Prior 
bevacizumab was allowed. There were no restrictions regarding histologic subtype of 
NSCLC, and central review was not required. Patients were required to have Eastern 
Cooperative Oncology Group performance status (PS) of 0 or 1 and adequate hematologic, 
liver, and kidney function defined by laboratory testing. Treated, asymptomatic brain 
metastases were allowed. Exclusion criteria included: symptomatic congestive heart failure, 
active coronary artery disease defined as myocardial infarction or unstable angina in the past 
year, cerebrovascular accident or transient ischemic accident in the past year, uncontrolled 
hypertension, hemoptysis, cavitary pulmonary lesions, history of thromboembolism, or 
requirement for full-dose therapeutic anticoagulation.
Study Design and Treatment
This was a randomized, open-label phase 2 study with patients randomized in a 1:1:1 
allocation to one of three arms: Arm I, pemetrexed alone at 500 mg/m2 on day 1; Arm II, 
sunitinib alone at 37.5 mg/day; and Arm III, pemetrexed 500 mg/m2 on day 1 with sunitinib 
37.5 mg daily. One cycle was considered 21 days. Randomization was stratified by PS (0/1), 
stage (IIIB/IV), and sex (male/female) using a stratified permuted block-randomization 
scheme.
The primary objective of the study was to estimate the 18-week PFS survival rate in each of 
the three arms of the study. Secondary objectives included: RRs, PFS, OS, and toxicity in 
the three arms.
The study was planned to randomize a total 225 eligible patients. With 75 patients in each 
arm, the study has at least 80% power to detect a 18-week PFS rate of 56.3% for either 
experimental arm (Arm II or III) versus the expected 18-week PFS rate of 37.1% for the 
control arm (Arm I) with each comparison performed at the one-sided 0.10 significance 
level.
The study was activated on April 15, 2008, and closed on September 15, 2011, after 130 
patients had been registered. Each participant signed an Institutional Review Board–
approved, protocol-specific informed consent in accordance with federal and institutional 
guidelines. The study was terminated early because of slow accrual and changing paradigms 
of therapy in metastatic NSCLC, specifically, the increased use of first-line or maintenance 
pemetrexed and the restriction of pemetrexed use to patients with nonsquamous histologies. 
The 130 registered patients were considered eligible and were randomized. Of them, five 
patients withdrew after randomization and did not receive protocol treatment. All 130 
patients who were registered and randomized were included in the final intention-to-treat 
analysis conducted in June 2013. Of note, analyses were also done excluding the five 
patients who did not receive protocol treatment, and the results were similar to those 
reported here. Data collection and statistical analyses were conducted by the Alliance 
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Statistics and Data Center. Data quality was ensured by review of data by the Alliance 
Statistics and Data Center and by the study chairperson following Alliance policies.
Assessments
Computed tomography scans of the chest and upper abdomen were obtained at baseline and 
at 6-week intervals. Radiographic review was done locally and Response Evaluation Criteria 
in Solid Tumors version 1.0 criteria were used to define response and progression. 
Specifically, progression was defined as at least a 20% increase in the sum of the longest 
diameter (LD) of target lesions, taking as references the smallest sum LD recorded since the 
treatment started, or the appearance of one or more new lesions. PFS was defined as the time 
from registration to disease progression or death from any cause, whichever came first. OS 
was defined as the time from registration to death of any cause. Adverse events were 
assessed and graded using National Cancer Institute Common Toxicity Criteria version 4.0. 
For additional safety monitoring, the initial cohort of 12 patients in the two experimental 
arms (Arms II and III) were followed for adverse events during the first cycle of therapy, 
with a stopping rule that if more than one-third of the initial patient cohort experienced a 
dose-limiting toxicity, then patient accrual would be stopped for the study team to review 
the cumulative safety data and make recommendations regarding changing the dose level or 
terminating the trial.
Statistical Analysis
The balance of baseline covariates between the treatment arms, including age, sex, race, 
histology, stage, PS, prior radiotherapy, prior surgery, and number of prior chemotherapy 
regimens (1, 2+), was tested using χ2 exact tests. The Kaplan–Meier product limit 
estimator10 was used to graphically describe OS and PFS. Median survival and 18-week 
survival rates by treatment arm, with 95% confidence intervals (CIs), were derived from the 
product limit estimates. Comparisons of PFS and OS were conducted using a log-rank test. 
The Cox proportional hazards model was used to estimate the hazard ratios and their 95% 
CIs of the experimental regimens relative to the control arm, with and without adjusting for 
baseline prognostic factors and their interactions with treatments. Backward selection was 
used for selecting significant baseline covariates and the interactions. The proportion of 
patients who responded (completely or partially) to each treatment regimen was estimated as 
well as their associated 95% CIs. Differences in RR (complete and partial response) were 
evaluated using the Cochran–Mantel–Haenszel test and using a multivariate logistic 
regression model. The type and grade of toxicity associated with each treatment regimen 
were summarized. The planned one-sided test on 18-week PFS between the arms was 
conducted and is reported in this article. However, because the outcome is contrary to the 
hypothesized direction, we also report the two-sided p value for this test, as two-sided p 
values are not dependent on the direction of hypothesized effects and are more appropriate 
for descriptive purposes. For all other statistical tests, two-sided p values were reported, and 
because of the small size of the final accruals, these p values are considered purely 
descriptive.
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Patients and Treatment Exposure
Between April 2008 and September 2011, 130 patients were registered: 42 in Arm I 
(pemetrexed alone), 47 in Arm II (sunitinib alone), and 41 in Arm III (pemetrexed + 
sunitinib). Median follow-up time was 36 months. Five patients did not receive protocol 
treatment after randomization (Fig. 1). Table 1 shows the clinical and demographic 
characteristics of the 130 patients. Baseline characteristics in the three arms were well 
balanced (all p > 0.10). The median age was 63 years, with a range from 38 to 84. Fifty-
three percent were male; 12% had stage IIIB disease and 88% stage IV. There were no 
significant differences between the treatment arms in age, sex, stage, PS, or number of prior 
chemotherapy regimens. Histologic diagnosis was predominantly adenocarcinoma (64% 
overall), with 13% squamous histology and no significant differences in histology 
distribution between the three arms.
Efficacy
Table 2 summarizes the best overall response. There were no complete responses. The rates 
of partial response and stable disease in the three arms were: pemetrexed (14% partial 
response [PR]/50% stable disease [SD]), sunitinib (17% PR/38% SD), pemetrexed + 
sunitinib (22% PR/51% SD). Despite a numerically higher PR rate in the combination arm, 
these differences were not statistically significant (p = 0.34).
More importantly, these PR rates did not translate to advantages in either PFS or OS for the 
combination arm (Table 3). The 18-week PFS rate in the three arms was not significantly 
different (2-df Wald test, one-sided p = 0.88 and two-sided p = 0.25), with an 18-week PFS 
rate in the pemetrexed arm of 54% (95% CI, 40–71), sunitinib 37% (95% CI, 25–54), and 
pemetrexed + sunitinib 48% (95% CI, 35–66). Median PFS was 4.9 months (95% CI, 2.1–
8.8) for pemetrexed alone, 3.3 months (95% CI, 2.3–4.2) for sunitinib alone, and 3.7 months 
(95% CI, 2.5–5.8) for pemetrexed + sunitinib (p = 0.18; Fig. 2A). The hazard ratio for 
sunitinib alone over pemetrexed alone is 1.4 (95% CI, 0.9–2.2) and that for pemetrexed + 
sunitinib over pemetrexed is 1.3 (95% CI, 0.9–2.1), estimated from a multivariate Cox 
model with adjustment for significant baseline covariates.
OS was significantly better with pemetrexed alone. Median OS was 10.5 months (95% CI, 
8.3–20.2) for pemetrexed alone, 8.0 months (95% CI, 6.8–13.5) for sunitinib alone, and 6.7 
months (95% CI, 4.1–10.1) for pemetrexed + sunitinib (p = 0.03; Fig. 2B). The hazard ratio 
for sunitinib alone over pemetrexed alone is 1.4 (95% CI, 0.9–2.3) and that for pemetrexed + 
sunitinib over pemetrexed is 2.0 (95% CI, 1.2–3.2), estimated from a multivariate Cox 
model with adjustment for significant baseline covariates.
Analysis of the squamous subset is exploratory only as there were only 17 squamous 
patients on study (Table 4). There was no benefit in PFS or OS to the sunitinib or 
pemetrexed + sunitinib arms in either the squamous or nonsquamous subsets. The OS 
benefit seen with pemetrexed alone was seen only in the nonsquamous arm.
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Table 5 shows the rates of grade 3 to 5 toxicities in the three arms. Overall, toxicity was 
higher in the sunitinib-containing arms compared with pemetrexed alone. There was 
significantly more fatigue in the sunitinib-containing arms, as well as more gastrointestinal 
side effects. Cardiovascular events and thrombotic/hemorrhagic events also clustered more 
in the sunitinib-containing arms although the absolute numbers of these were small. Of the 
five grade 5 events, two (hemoptysis in the sunitinib arm and pneumonia in setting of 
neutropenia in pemetrexed + sunitinib arm) were thought to be treatment related, and one 
(pulmonary embolus in pemetrexed + sunitinib arm) was thought probably treatment related. 
The grade 5 hemoptysis death occurred in a patient with adenocarcinoma.
Because there were only 17 squamous patients on study, a comparison of toxicity between 
squamous and nonsquamous is limited by small sample size. However there was no obvious 
signal for increased toxicity in the squamous patients.
DISCUSSION
In this randomized phase 2 study, we investigated the role of sunitinib in the second-line 
setting in NSCLC by treating patients with either pemetrexed alone, sunitinib alone, or the 
combination of pemetrexed and sunitinib. The primary end point, 18-week PFS rate, was not 
significantly different between the three arms. However, there was a trend toward improved 
PFS with pemetrexed alone, and OS was significantly better with pemetrexed alone. In 
addition, we found that pemetrexed had a superior safety profile to either sunitinib or the 
combination of pemetrexed and sunitinib.
This study was closed prematurely because of slowing accrual rates. The slow accrual was 
thought to be a result of global changes in management in NSCLC, specifically the 
increased adoption of maintenance chemotherapy as well as the increasing limitation of 
pemetrexed to nonsquamous histology only. Therefore, the study as completed is not 
adequately powered to address the primary end point of difference in 18-week PFS rate. 
Despite this, the study suggests that pemetrexed remains the best treatment option in this 
setting and the single-agent activity of sunitinib or the addition of sunitinib to pemetrexed 
yielded no benefit. This validates our approach of carefully exploring treatment options in a 
phase 2 setting before committing to phase 3 trials and reconfirms the very limited role of 
antiangiogenic drugs thus far in lung cancer.
It is not entirely clear why the OS was superior in the pemetrexed alone arm. Of note, there 
were significantly fewer patients in the pemetrexed plus sunitinib arm who subsequently 
went on to receive further lines of therapy (54% in pemetrexed alone arm received 
subsequent chemotherapies, 63% in sunitinib arm, and 22% in pemetrexed plus sunitinib 
arm). Within each treatment arm, patients who received subsequent therapies had 
significantly longer survival than those without. Whether the relative lack of subsequent 
therapies in the combination arm is simply a reflection of the worse outcomes seen in that 
arm, or possibly contributed to that worse survival, is unknown. Although similar 
percentages of patients in the sunitinib only and pemetrexed only arms went on to receive 
further therapies, the median PFS in the sunitinib arm is the shortest of the three treatment 
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regimens and it is possible that the limited activity of sunitinib in the second-line setting 
contributed to the shorter OS in that arm relative to the pemetrexed only arm.
Other trials combining VEGFR tyrosine kinase inhibitors with chemotherapy have yet to 
show a benefit to the combination. Many of these studies demonstrate higher rates of 
adverse events with combination therapy. A phase 3 study in the first-line setting of 
carboplatin and paclitaxel with or without sorafenib was terminated early when interim 
analysis concluded that the study was highly unlikely to meet its primary end point of OS 
benefit. Of note, patients with squamous histology had greater mortality in the combination 
arm.11 BR24, a large randomized phase 2/3 study in first-line NSCLC of carboplatin and 
paclitaxel with cediranib or placebo, was halted after the phase 2 portion as rates of serious 
adverse events were significantly higher in the cediranib arm.12 However, because of signals 
of potential clinical benefit, with a statistically significant higher RR and trend toward better 
PFS in the cediranib arm, plans to proceed at a 20 mg dose of cediranib in the phase 3 
setting are underway. In the previously treated setting, the combination of sunitinib with 
erlotinib did not improve OS over erlotinib alone, despite statistically significant 
improvements in RR and PFS.13 Again, treatment-related adverse events were higher with 
the combination.
Similar to these studies, we found a higher rate of adverse events in the sunitinib-containing 
arms. Although we did not have a large proportion of squamous patients on the current 
study, there was no signal that the squamous patients in particular did any worse in terms of 
toxicity than the non-squamous patients. Whether the relatively less toxicity seen with 
pemetrexed alone was another factor in the improved OS is also a possibility. Overall grade 
3 to 4 toxicity was higher in this study in the sunitinib-containing arms as compared with the 
pemetrexed alone arm. Differences in these side effects can be quite clinically significant for 
patients, particularly as significant fatigue or gastrointestinal side effects may impact 
patients’ PS, ability to tolerate current therapies, and fitness and tolerance for future 
therapies.
Whether a subset of patients exists who would derive benefit from sunitinib remains an open 
question. As a multitargeted agent, sunitinib inhibits multiple kinases other than the VEGFR 
and is not solely an antiangiogenic agent. In particular, the inhibitory activity against RET 
and PDGFR are of interest. Recently, RET kinase fusions have been identified as a novel 
potential oncogenic driver in lung cancer.14-17 The most common fusion partner in lung 
cancer is KIF5B although CCDC6-RET fusions have been reported as well. The fusion gene 
causes overexpression of the RET receptor tyrosine kinase and occurs in approximately 1% 
to 2% of lung adenocarcinomas. Cell lines engineered to harbor the RET fusion have been 
shown to be transforming, and sensitive to several multitargeted kinase inhibitors that inhibit 
RET, including sunitinib, sorafenib, and vandetanib. Another potential biomarker for 
sunitinib response may be PDGFRA amplification. High throughput cell line screening 
revealed that two of 637 cell lines had significant sensitivity to single-agent sunitinib.18 
Both of these cell lines (one NSCLC and one rhabdomyosarcoma) showed PDGFRA 
activation with high levels of expression of phosphorylated PDGFRA, with focal PDGFRA 
gene amplification seen in the NSCLC cell line.
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Although these data from cell lines for RET fusion and PDGFRA amplification are 
suggestive, there are as yet no clinical data that such molecular changes in patients confer 
sensitivity to sunitinib. This trial did not mandate tumor collection from patients and the 
small sample size would make the likelihood of finding any specific genetic alteration quite 
low. However, future studies investigating this question would be of interest to determine 
whether specific molecularly defined subsets of patients may benefit from sunitinib.
This study has several limitations that should temper any interpretation of these results. We 
were able to accrue only a little over half the goal accrual for this study. The limited sample 
size severely limits our ability to draw definitive conclusions from this data. Variation 
between the arms may be a function of small numbers. Ultimately, however, this study does 
not support the use of sunitinib in the second-line setting in NSCLC.
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CONSORT diagram. AST, aspartate transaminase, BP, blood pressure.
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A, Progression-free survival. B, Overall survival.
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Age, median: 63; range (38–84)
 <60 16 (38%) 15 (32%) 15 (37%) 46 (35%)
 60–70 15 (36%) 24 (51%) 13 (32%) 52 (40%)
 ≥70 11 (26%) 8 (17%) 13 (32%) 32 (25%)
Sex
 Male 22 (52%) 25 (53%) 22 (54%) 69 (53%)
 Female 20 (48%) 22 (47%) 19 (46%) 61 (47%)
Race
 White 36 (86%) 43 (91%) 32 (78%) 111 (85%)
 Black 5 (12%) 3 (6%) 8 (20%) 16 (12%)
 Asian 0 (0%) 1 (2%) 1 (2%) 2 (1%)
 More than one race 1 (2%) 0 (0%) 0 (0%) 1 (1%)
Ethnicity
 Non-Hispanic 39 (93%) 47 (100%) 36 (88%) 122 (94%)
 Hispanic 2 (5%) 0 (0%) 1 (2%) 3 (2%)
 Unknown 1 (2%) 0 (0%) 4 (10%) 5 (4%)
Histology
 Adenocarcinoma 28 (67%) 28 (60%) 27 (66%) 83 (64%)
 Squamous cell 4 (10%) 7 (15%) 6 (15%) 17 (13%)
 Large cell 2 (5%) 4 (9%) 0 (0%) 6 (5%)
 Undifferentiated NSC 3 (7%) 6 (13%) 1 (2%) 10 (8%)
 Other 3 (7%) 2 (4%) 7 (17%) 12 (9%)
 Missing 2 (5%) 0 (0%) 0 (0%) 2 (2%)
Stage
 IIIB 5 (12%) 8 (17%) 3 (7%) 16 (12%)
 IV 37 (88%) 39 (83%) 38 (93%) 114 (88%)
Prior surgery
 No 24 (57%) 34 (72%) 30 (73%) 88 (68%)
 Yes 16 (38%) 12 (26%) 11 (27%) 39 (30%)
 Missing 2 (5%) 1 (2%) 0 (0%) 3 (2%)
Prior XRT
 No 22 (52%) 26 (55%) 21 (51%) 69 (53%)
 Yes 17 (40%) 21 (45%) 20 (49%) 58 (45%)
 Missing 3 (7%) 0 (0%) 0 (0%) 3 (2%)
No. of prior chemo regimens
 1 38 (90%) 43 (91%) 39 (95%) 120 (92%)
 2+ 1 (2%) 4 (9%) 0 (0%) 5 (4%)
 Missing 3 (7%) 0 (0%) 2 (5%) 5 (4%)
Performance status
































 0 13 (31%) 17 (36%) 14 (34%) 44 (34%)
 1 29 (69%) 30 (64%) 27 (66%) 86 (66%)
NSC, non-small cell lung cancer; XRT, radiation.
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